Eli Lilly and Co (WAR:LILY) Margin of Safety % (DCF Dividends Based): N/A (As of Jul. 21, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

WAR:LILY Eli Lilly and Co WAR:LILY
31 GF Score
Price zł4,422.00
GF Value zł5,634.61
Valuation Modestly Undervalued
! 5 Warning Signs
View Full Analysis

What is Eli Lilly and Co Margin of Safety % (DCF Dividends Based)?

Margin of Safety % (DCF Dividends Based) = (Intrinsic Value: DCF (Dividends Based) - Current Price) / Intrinsic Value: DCF (Dividends Based).

Note: Discounted Dividend model is only suitable for companies who have a consistant distribution history with more than 5 years. If the company's dividends does not remain steady over a long period, results may not be accurate due to the low consistency. The model is also only suitable for predictable companies (Business Predictability Rank higher than 1-Star). If the company's Predictability Rank is 1-Star or Not Rated, the data will not be stored into our database.

As of today (2026-07-21), Eli Lilly and Co's Predictability Rank is 3.5-Stars. Eli Lilly and Co's intrinsic value calculated from the Discounted Dividend model is zł2887.02 and current share price is zł4422.00. Consequently,

Eli Lilly and Co's Margin of Safety % (DCF Dividends Based) using Discounted Dividend model is N/A.

WAR:LILY vs JNJ, ABBV, MRK: Margin of Safety % (DCF Dividends Based) Comparison

For the Drug Manufacturers - General subindustry, Eli Lilly and Co's Margin of Safety % (DCF Dividends Based), along with its competitors' market caps and Margin of Safety % (DCF Dividends Based) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Eli Lilly and Co Margin of Safety % (DCF Dividends Based) vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Eli Lilly and Co's Margin of Safety % (DCF Dividends Based) distribution charts can be found below:

* The bar in red indicates where Eli Lilly and Co's Margin of Safety % (DCF Dividends Based) falls into.


WAR:LILY
31GF Score
Eli Lilly and Co WAR:LILY
Margin of Safety % (DCF Dividends Based) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Eli Lilly and Co Margin of Safety % (DCF Dividends Based) Calculation

Eli Lilly and Co's Margin of Safety % (DCF Dividends Based) for today is calculated as

Margin of Safety % (DCF Dividends Based)=(Intrinsic Value: DCF (Dividends Based)-Current Price)/Intrinsic Value: DCF (Dividends Based)
=(0.00-4422.00)/0.00
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The intrinsic value is calculated from the Discounted Dividend model with default parameters.

Is Eli Lilly and Co (WAR:LILY) Overvalued in 2026?

Based on GuruFocus' analysis, Eli Lilly and Co stock appears to be undervalued. The current stock price of zł4,422.00 is trading 21.5% below its estimated GF Value™ of zł5,634.61. GuruFocus considers Eli Lilly and Co to be Modestly Undervalued.

Key valuation signals for WAR:LILY:

  • Margin of Safety % (DCF Dividends Based): N/A
  • GF Value™: zł5,634.61 vs. price of zł4,422.00 (21.5% below fair value)
  • GF Score™: 31/100 with 5 warning signs

No single metric tells the full story. See the WAR:LILY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Eli Lilly and Co Business Description

Address Lilly Corporate Center, Indianapolis, IN, USA, 46285
Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio and Jaypirca for cancer; Mounjaro, Zepbound, Foundayo, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.
31GF Score

Get the complete analysis for WAR:LILY

Margin of Safety % (DCF Dividends Based) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

zł4,422.00
Price
zł5,634.61
GF Value